Nectin-4与膀胱癌:核医学诊疗一体化的前沿
本文综述Nectin-4在膀胱癌中的作用及其核医学诊疗一体化潜力。Nectin-4在尿路上皮癌中高表达(约60%-87%),与晚期疾病和不良预后相关;FDA批准的ADC enfortumab vedotin验证了其靶向价值,客观缓解率约40%-50%。Nectin-4靶向PET显像(如68Ga标记药物)和放射性核素治疗(如225Ac、177Lu标记药物)初步显示良好靶向性、疗效与安全性。
要点
- Nectin-4在尿路上皮癌中高表达,是膀胱癌诊疗一体化的新兴靶点
- 68Ga标记Nectin-4靶向PET显像可实现精准患者筛选
- 225Ac/177Lu标记药物临床前及早期临床显示良好靶向与安全性
核心结论
- 靶向Nectin-4是膀胱癌管理的新前沿,连接分子诊断与个性化靶向放射性核素治疗。
研究设计与样本
- 综述类文章,检索范围未在摘要中明确报告,文中汇总了Nectin-4在膀胱癌中的表达、影像与治疗研究证据。
主要发现
- Nectin-4在尿路上皮癌中高表达(约60%-87%),与晚期疾病和较差预后相关。
- FDA批准的ADC enfortumab vedotin验证Nectin-4靶向,客观缓解率约40%-50%,显著改善难治性晚期尿路上皮癌生存。
- 68Ga标记Nectin-4靶向PET显像展示良好肿瘤定位与特异性,支持精准患者筛选。
- 225Ac及177Lu标记放射性核素药物在临床前及早期临床显示有希望的疗效、稳健肿瘤靶向与良好安全性。
关键数值与推荐
- Nectin-4在尿路上皮癌中过表达比例约60%-87%。
- enfortumab vedotin靶向Nectin-4的客观缓解率约40%-50%。
临床怎么用
- 可利用Nectin-4靶向PET显像筛选适合靶向治疗的患者。
- 放射性核素治疗(如225Ac、177Lu标记药物)有望用于Nectin-4阳性膀胱癌的精准治疗与监测。
局限性
- 摘要未报告综述的检索策略、纳入研究数量及偏倚评估等局限性信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Bladder cancer is among the top ten most common cancers globally, with advanced or metastatic disease associated with dismal survival outcomes. Current diagnostic imaging and therapies have significant limitations, highlighting the urgent need for novel theranostic targets. Nectin-4, a cell adhesion molecule frequently overexpressed in bladder cancer, especially urothelial carcinoma (∼60%-87% of tumors), has emerged as a promising biomarker and therapeutic target. This review critically evaluates the role of Nectin-4 in bladder cancer and explores its exciting potential in nuclear medicine for combined molecular imaging and targeted radionuclide therapy-embracing the "theranostic" paradigm. Nectin-4 is abundantly and selectively expressed in most urothelial carcinomas, correlating with advanced disease and poorer prognosis. Clinically validated by the FDA-approved antibody-drug conjugate enfortumab vedotin, Nectin-4 targeting achieves objective response rates around 40%-50% and significantly improves survival in refractory advanced urothelial carcinoma. Recent clinical advances in Nectin-4-targeted PET imaging (such as 68Ga-labeled agents) have demonstrated excellent tumor localization and specificity, enabling precise patient selection for targeted therapies. Additionally, emerging radionuclide therapeutics (eg, 225Ac- and 177Lu-based agents) show promising preclinical and early clinical efficacy, robust tumor targeting, and favorable safety profiles. Targeting Nectin-4 represents a new frontier in the management of bladder cancer, bridging the gap between precise molecular diagnostics and personalized targeted radionuclide therapy. Ongoing clinical trials and translational research are rapidly advancing this promising theranostic strategy towards routine clinical application, with significant potential to enhance patient selection, treatment monitoring, and ultimately, clinical outcomes.
引用
- Kabunda J, Ndlovu H, Singh K, et al. Nectin-4, Bladder Cancer, and Nuclear Medicine: A Theranostic Frontier. Semin Nucl Med. 2025. PMID: 41015659. doi:10.1053/j.semnuclmed.2025.09.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。